Novo Nordisk’s Big Comeback: Why Analysts Are Turning Bullish Again
Novo Nordisk (NYSE: NVO) just faced a 54% collapse, but its groundbreaking CagriSema drug and $5.2B Akero acquisition could reignite growth. The pipeline looks strong, Wall Street is turning bullish again, and the leadership shake-up may be the setup for a stunning recovery. Stock prices used were the market prices of Oct. 28, 2025. The … Read more